Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Niran Amar

Allergy & Immunology Waco, TX Medical Doctor

NPI 1003812595 CMS profile 181661

333 Londonderry Dr, Ste 100, Waco, TX 76712

Open in the dashboard

General payments

$6,184

349 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$834,107 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Niran Amar of Waco, TX is reported in the CMS Open Payments database as having received $6,184 across 349 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $834,107 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 61st percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $769 30
2024 General $670 23
2023 General $641 44
2022 General $1,077 60
2021 General $943 60
2020 General $532 33
2019 General $1,552 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Niran Amar
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Niran Amar were reported at $769. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Niran Amar Allergy & Immunology median Middle half National median
2019 $1,552 $594 $163–$1,512 $163
2020 $532 $426 $106–$1,233 $114
2021 $943 $638 $157–$1,708 $132
2022 $1,077 $790 $205–$1,961 $149
2023 $641 $852 $220–$2,147 $160
2024 $670 $865 $203–$2,267 $164
2025 $769 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $548 37 payments
  2. CSL Behring $514 30 payments
  3. Novo Nordisk Inc $441 30 payments
  4. AstraZeneca Pharmaceuticals LP $309 17 payments
  5. Genzyme Corporation $276 15 payments
  6. Xeris Pharmaceuticals, Inc. $273 15 payments
  7. Regeneron Healthcare Solutions, Inc. $259 8 payments
  8. Novartis Pharmaceuticals Corporation $250 14 payments
  9. Octapharma USA, Inc. $221 4 payments
  10. Jubilant HollisterStier LLC $193 1 payment
  11. Other $2,900 178 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,052 347 payments
  2. Education $132 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $303 21 payments
  2. Hizentra $278 14 payments
  3. Haegarda $235 16 payments
  4. CUTAQUIG $221 4 payments
  5. TRELEGY ELLIPTA $212 14 payments
  6. RYBELSUS $183 11 payments
  7. NUCALA $176 19 payments
  8. DUPIXENT Immunology $170 11 payments
  9. DUPIXENT Inflammation And Immunology $160 7 payments
  10. Tymlos $159 7 payments
  11. Other $5,150 311 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,737

Median for Allergy/ Immunology: 449

Drug cost

$330,694

Median for Allergy/ Immunology: $169,700

Branded share of claims

37%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 159 $129,030
Dupixent Syringe Dupilumab Brand 16 $59,873
Breo Ellipta Fluticasone/Vilanterol Brand 35 $22,792
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 28 $20,643
Symbicort Budesonide/Formoterol Fumarate Brand 54 $18,744
Epinephrine Generic 93 $18,673
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 53 $9,586
Fluticasone Propionate Generic 344 $8,725
Azelastine-Fluticasone Azelastine/Fluticasone Brand 37 $7,567
Azelastine Hcl Generic 212 $6,767

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$94,924

Of which drugs: $2,608

Medicare patients

272

Average age 74

Services billed

9,280

173 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 24%
Diabetes 23%
Depression 21%
Osteoporosis 18%
Chronic kidney disease 17%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 31 31 $2,527

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AYVAKIT
  • Blueprint Medicines Corporation $73
$73 — —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $55
$55 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $37
$37 — —
Haegarda
  • CSL Behring $36
$36 — —
Hizentra
  • CSL Behring $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

349 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record